Voyager Therapeutics is a biotechnology company that is headquartered in Cambridge, Massachusetts that was founded by Guangping Gao, Krystof Bankiewicz, Mark Kay, and Phillip D. Zamore in 2014. The company is developing novel gene therapies using the adeno-associated virus (AAV) for the treatment of neurological disorders such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, and Alzheimer's disease.
On February 11, 2015 Voyager Therapeutics announced they raised $30 million in their corporate funding round from Genzyme.
On February 12, 2014 Voyager Therapeutics closed their series A funding round with $45 million in funding from Third Rock Ventures.
On April 13, 2015 Voyager Therapeutics closed their series B funding round with $60 million in funding from Wellington Management, Partner Fund Management, Fidelity Management and Research Company, Casdin Capital, and Brookside Capital.
Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson's Disease and Provides Clinical Update
Global News Wire
Documentaries, videos and podcasts